ISOPet™
RadioGel™ | Yttrium-90 (Y-90) Brachytherapy Products for Veterinary Applications
March 15th, 2016, Vivos Inc. announced the formation of a new, wholly-owned subsidiary, IsoPet® Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market. August 2017, the subsidiary was eliminated and changed into a separate operating division inside the Company.
The IsoPet® Solutions division will focus on bringing RadioGel™ yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor
cancers.
There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat. IsoPet® Solutions is
establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education
to veterinary oncologists. Initial treatments are to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory
Board, Dr. Alice Villalobos.
CEO and President Dr. Mike Korenko stated: “IsoPet® Solutions allows specific resources to focus on the use of our RadioGel™ Yttrium-90 brachytherapy products in the veterinary space. We believe that RadioGel™ is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”
Dr. Alice stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as RadioGel™ Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."
Learn more about RadioGel's™ first companion animal treatments through a study at Washington State University funded by the Washington State Life Sciences Discovery Fund for the treatment of feline sarcoma.